Join us for AMCP Nexus 2025 in National Harbor from October 27-30, 2025. Watch video sizzle reel!
Best Practice Handout - Health Plan Best Practice – Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin. View the fact sheet on JMCP that includes:
- Current Recommended Treatments in CLL
- What Oncology Specialists Recommend Various First-Line CLL Treatments
- Suggested Treatment Algorithm in Patients Intolerant of 1st Generation BTK Inhibitor
- Important Factors to Consider when Calculating the Total Cost of Care for CLL
- Suggested CLL/SLL Treatment Pathways
For more disease state research, view the Market Insights Program.
Related
AMCP strongly supports the passage of the MVP Act. Medicaid beneficiaries are among America's most vulnerable patients. Value-based payment arrangements are a critical tool for promoting patient access to high-quality, affordable care.
AMCP supports the Ensuring Community Access to Pharmacist Services Act. This bill will help ensure that Americans can continue to rely on pharmacists as essential partners in pandemic preparedness and response. The ECAPS Act will also improve patient access to tests and treatments by authorizing pharmacists to provide these services and receive reimbursement under Medicare Part B. The ECAPS Act addresses disparities in public health preparedness in medically underserved communities like rural areas by allowing these patients to seek care from their most accessible provider.
Featured News & Resources
See Full Calendar
Other Events
2026 Call for AMCP Board Applications
National Meetings
Midwest AMCP Chicago Day of Education
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
